Metsera (MTSR) said late Thursday it priced its initial public offering of about 15.3 million common shares at $18 per share for expected gross proceeds of $275 million.
The biotechnology company granted the underwriters a 30-day option to purchase up to roughly 2.3 million additional shares.
Closing of the offering is expected to occur on Feb. 3, subject to customary conditions.
The shares are expected to begin trading on the Nasdaq Global Select Market on Friday under the ticker "MTSR."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.